tert-butyl 4-(4-((tert-butoxycarbonyl (2-chloro-5-methoxy-4-nitrophenethyl)amino)methyl)phenyl)piperazine-1-carboxylate | 1349745-17-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: tert-butyl 4-(4-((tert-butoxycarbonyl (2-chloro-5-methoxy-4-nitrophenethyl)amino)methyl)phenyl)piperazine-1-carboxylate
• 英文别名: tert-butyl 4-[4-[[2-(2-chloro-5-methoxy-4-nitrophenyl)ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]piperazine-1-carboxylate
• CAS: 1349745-17-0
• 化学式: C₃₀H₄₁ClN₄O₇
• 分子量: 605.131
• InChiKey: NGHWRHXFVFWCNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-((tert-butoxycarbonyl (2-chloro-5-methoxy-4-nitrophenethyl)amino)methyl)phenyl)piperazine-1-carboxylate 在 氯化铵 、 锌 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以97%的产率得到tert-butyl-4-(4-(((4-amino-2-chloro-5-methoxyphenethyl)(tert-butoxycarbonyl)amino)methyl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] MODULATORS OF CHK-1 ACTIVITY
  [FR] COMPOSÉS PHARMACEUTIQUES

  摘要：

  公开号：

  WO2011141716A3
• 作为产物：
  描述：

  1-chloro-4-methoxy-5-nitro-2-vinylbenzene 在 三乙胺 、 对苯二酚 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 31.0h， 生成 tert-butyl 4-(4-((tert-butoxycarbonyl (2-chloro-5-methoxy-4-nitrophenethyl)amino)methyl)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] MODULATORS OF CHK-1 ACTIVITY
  [FR] COMPOSÉS PHARMACEUTIQUES

  摘要：

  公开号：

  WO2011141716A3

文献信息

• PHARMACEUTICAL COMPOUNDS
  申请人：Boyle Robert George

  公开号：US20130065900A1

  公开（公告）日：2013-03-14

  The invention provides a compound of the formula (1): or a salt, N-oxide or tautomer thereof; wherein R 1 is cyano or C 1-4 alkyl; R 2 is hydrogen or C 1-4 alkyl; R 3 is hydrogen or C 1-4 alkyl; R 4 and R 5 are the same or different and each is selected from hydrogen, saturated C 1-4 hydrocarbyl and saturated C 1-4 hydrocarbyloxy; R 6 and R 7 are the same or different and each is selected from hydrogen, halogen, CN, C 1-4 alkyl and C 1-4 alkoxy wherein the C 1-4 alkyl and C 1-4 alkoxy are each optionally substituted with hydroxy, C 1-2 alkoxy or by one or more flourine atoms; R 8 is hydrogen or C 1-4 alkyl; Q is an alkylene chain of 1 to 4 carbon atoms in length between the moiety Ar and the nitrogen atom N, wherein one or more of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with one or two C 1-4 alkyl groups, or wherein one carbon atom of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with a group —CH 2 CH 2 — which together with the said one carbon atom forms a cyclopropyl group; m is 1, 2, 3 or 4; n is 0 or 1; and Ar is a monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members containing 0, 1, 2, 3 or 4 heteroatom ring members selected from O, N and S, the aryl or heteroaryl group being optionally substituted with one to four substituents R 13 as defined in the claims. The compounds are inhibitors of Chk-1 kinase and are active against cancers.

  本发明提供了化合物的公式（1）：或其盐，N-氧化物或互变异构体；其中R1是氰基或C1-4烷基；R2是氢或C1-4烷基；R3是氢或C1-4烷基；R4和R5相同或不同，每个都选择自氢，饱和的C1-4烃基和饱和的C1-4烃基氧；R6和R7相同或不同，每个都选择自氢，卤素，CN，C1-4烷基和C1-4烷氧，其中C1-4烷基和C1-4烷氧均可选地用羟基，C1-2烷氧或一个或多个氟原子取代；R8是氢或C1-4烷基；Q是长度为1到4个碳原子的烷基链，在基团Ar和氮原子N之间，其中1到4个碳原子中的一个或多个可以可选地用一个或两个C1-4烷基取代，或其中1个碳原子可以可选地用一个—CH2CH2—基团取代，与所述1个碳原子一起形成环丙基基团；m为1、2、3或4；n为0或1；Ar是一个含有0、1、2、3或4个杂环原子环成的5到10个环成员的单环或双环芳基或杂芳基，所述芳基或杂芳基可选地用一到四个定义如权利要求中所定义的取代基R13取代。这些化合物是Chk-1激酶的抑制剂，对癌症具有活性。
• Pharmaceutical compounds
  申请人：Boyle Robert George

  公开号：US08716287B2

  公开（公告）日：2014-05-06

  A compound of the formula (I):

  化合物的式子（I）：
• US8716287B2
  申请人：——

  公开号：US8716287B2

  公开（公告）日：2014-05-06
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2011141716A2

  公开（公告）日：2011-11-17

  The invention provides a compound of the formula (1): or a salt, N-oxide or tautomer thereof; wherein R1 is cyano or C1-4 alkyl; R2 is hydrogen or C1-4 alkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 are the same or different and each is selected from hydrogen, saturated C1-4 hydrocarbyl and saturated C1-4 hydrocarbyloxy; R6 and R7 are the same or different and each is selected from hydrogen, halogen, CN, C1-4 alkyl and C1-4 alkoxy wherein the C1-4 alkyl and C1-4 alkoxy are each optionally substituted with hydroxy, C1-2 alkoxy or by one or more flourine atoms; R8 is hydrogen or C1-4 alkyl; Q is an alkylene chain of 1 to 4 carbon atoms in length between the moiety Ar and the nitrogen atom N, wherein one or more of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with one or two C1-4 alkyl groups, or wherein one carbon atom of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with a group -CH2CH2- which together with the said one carbon atom forms a cyclopropyl group; m is 1, 2, 3 or 4; n is 0 or 1; and Ar is a monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members containing 0, 1, 2, 3 or 4 heteroatom ring members selected from O, N and S, the aryl or heteroaryl group being optionally substituted with one to four substituents R13 as defined in the claims. The compounds are inhibitors of Chk-1 kinase and are active against cancers.